![CDK4/6 Inhibitors in Early-stage Breast Cancer](https://www.aacr.org/wp-content/uploads/2024/01/03-CDK-600x450-1-380x265.jpg)
CDK4/6 Inhibitors in Early-stage Breast Cancer
A mainstay of treatment for metastatic breast cancer, CDK4/6 inhibitors are moving into early-stage treatment.
A mainstay of treatment for metastatic breast cancer, CDK4/6 inhibitors are moving into early-stage treatment.
Highlights of December 2023 AACR journals include clinical trial results, strategies to improve therapy, and a new cervical cancer screening method.
Researchers focus on assessing quality of life and toxicity risks in people with breast cancer.
Evidence grows that some people with HER2-positive breast cancer may do well on HER2-targeted therapy alone.
With a five-year survival rate of only 12.5%, any progress toward new therapeutic approaches for pancreatic cancer is welcomed by patients and their families. At present, increasingly complex chemotherapy regimens offer only marginal improvements...
As you prepare for trick-or-treating, check out the articles selected by the editors of the 10 AACR journals for the month of October. Highlights include studies on the regulation of electrical activity between melanoma...
Neuroblastoma, a rare cancer that occurs primarily in children, is a scientific paradox, said pediatric oncologist John M. Maris, MD, of Children’s Hospital of Philadelphia (CHOP). “On one hand, a fairly high percentage of...
As the temperatures start to drop and the leaves begin to change color, enjoy the latest selection of studies hand-picked by the editors of the 10 AACR journals. These include reports on a novel...
Forum for patient advocates explores how researchers are working to develop cancer treatments in a quicker, more efficient manner.
Based on estimates from the National Cancer Institute, in 2023, more than 110,000 cases of gynecologic cancers are expected to be diagnosed in the U.S., and approximately 34,000 people will die from these diseases. ...